You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Postoperative Infection May Influence Survival in Patients With Glioblastoma: Simply a Myth?

De Bonis, Pasquale MD*‡; Albanese, Alessio MD*‡; Lofrese, Giorgio MD‡; de Waure, Chiara MD§; Mangiola, Annunziato MD‡; Pettorini, Benedetta Ludovica MD‖; Pompucci, Angelo MD‡; Balducci, Mario MD¶; Fiorentino, Alba MD¶; Lauriola, Libero MD#; Anile, Carmelo MD‡; Maira, Giulio MD‡

Neurosurgery:
doi: 10.1227/NEU.0b013e318222adfa
Research-Human-Clinical Studies
Abstract

BACKGROUND: It is a prevalent myth that a postoperative infection may actually confer a survival advantage in patients with malignant glioma. This contention is based largely on anecdotal reports. Recently, a single-center study showed there was no survival advantage in those patients who had glioblastoma with postoperative infection.

OBJECTIVE: To examine the impact of postoperative infections on outcome in patients with glioblastoma treated at our center.

METHODS: This study included 197 patients with newly diagnosed primary glioblastoma treated from January 2001 to January 2008. Of the 197 patients, 10 (5.08%) had postoperative bacterial infection. The Kaplan-Meier method, log-rank test, and Breslow test were used in the univariate approach; Cox regression was used in the multivariable approach.

RESULTS: The median survival was 16 months (95% confidence interval [CI], 14-18 mo). The infection group had a significant advantage in the median survival: 30 months (95% CI, 21-39) vs 15 months (95% CI, 13-17) for patients without postoperative infection. This advantage was also confirmed by Cox regression; in fact, patients not developing a postoperative infection showed an adjusted hazard ratio for death of 2.3 (95% CI, 1-5.3).

CONCLUSION: The association between infection and prolonged survival is not definitive; we acknowledge the considerable difficulties in undertaking this type of study in a retrospective manner. Our results can instead stimulate further multicentric studies (to increase the number of patients) or experimental studies using genetically modified bacteria for treatment of glioblastoma.

Author Information

*These authors have contributed equally to this article.

Institutes of ‡Neuro-surgery, §Hygiene, ¶Radiotherapy, and #Pathology, Catholic University School of Medicine, Rome, Italy; ‖Department of Neurosurgery, Birmingham Children's Hospital, Birmingham, England

Received, August 5, 2010.

Accepted, March 11, 2011.

Published Online, May 5, 2011.

Correspondence: Pasquale De Bonis, MD, Institute of Neurosurgery, Catholic University School of Medicine, L. go A. Gemelli, 8–00168, Rome, Italy. E-mail: debonisvox@gmail.com

Copyright © by the Congress of Neurological Surgeons